LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia
Rhea-AI Summary
LENZ (NASDAQ: LENZ) submitted a Marketing Authorization Application to the European Medicines Agency for VIZZ® (aceclidine ophthalmic solution) 1.44% for presbyopia on March 10, 2026. This is the fifth ex‑U.S. regulatory submission for VIZZ and follows U.S. FDA approval in July 2025.
Submission is supported by three randomized Phase 3 CLARITY trials that met all primary and secondary endpoints, showing near‑vision improvement within 30 minutes lasting up to 10 hours and no serious treatment‑related adverse events in over 30,000 treatment days.
Positive
- MAA submission to EMA advances European regulatory review for VIZZ
- Three Phase 3 CLARITY trials met all primary and secondary endpoints
- U.S. FDA approval in July 2025 enables existing commercial availability
- Safety dataset: no serious treatment‑related adverse events in >30,000 treatment days
Negative
- EMA review is pending and approval is not guaranteed, creating regulatory timing risk
News Market Reaction – LENZ
In the Mar 10 session, LENZ declined 2.93%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Investor conferences | Neutral | +2.6% | Management participation in March investor conferences and webcast availability. |
| Jan 14 | Brand campaign launch | Positive | +12.0% | Consumer campaign with celebrity ambassador promoting VIZZ for presbyopia. |
| Jan 07 | Prelim Q4 results | Positive | -6.6% | Preliminary Q4 2025 results and commercial ramp details for VIZZ. |
| Jan 05 | Middle East deal | Positive | +3.0% | Exclusive Middle East commercialization partnership for VIZZ with Lunatus. |
| Dec 01 | NDA submission | Positive | -0.4% | South Korea MFDS NDA for VIZZ based on positive CLARITY Phase 3 data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
LENZ often reacts positively to commercial and branding updates, while some regulatory and financial milestones have seen muted or negative price responses.
Over the past few months, LENZ has focused on expanding VIZZ globally and building its commercial presence. On Dec 1, 2025, a South Korea NDA submission used positive Phase 3 CLARITY data. Early Jan 2026 brought a Middle East commercialization partnership and preliminary Q4 2025 financials, including initial U.S. sales. A celebrity-led consumer campaign on Jan 14, 2026 coincided with a strong share move. Today’s EMA MAA filing continues this strategy of broadening VIZZ’s international footprint.
Key Terms
marketing authorization application regulatory
european medicines agency regulatory
presbyopia medical
phase 3 medical
double-masked medical
ophthalmic medical
ema regulatory
u.s. food and drug administration regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
MAA submission to the European Medicines Agency represents a key regulatory milestone in LENZ’s strategy to expand global access to VIZZ
Submission of MAA in Europe results in the fifth ex-U.S. regulatory submission for VIZZ
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the review and approval of VIZZ® (aceclidine ophthalmic solution)
The MAA submission is supported by positive data from three randomized, double-masked, controlled Phase 3 studies (CLARITY trials) conducted in the United States, in which VIZZ achieved all primary and secondary endpoints, demonstrating the ability to improve near vision within 30 minutes and last up to 10 hours. VIZZ was well tolerated with no serious treatment-related adverse events observed in over 30,000 treatment days across all three CLARITY trials.
VIZZ was approved by the U.S. Food and Drug Administration (FDA) in July 2025 and is commercially available in the United States. The EMA submission marks the fifth ex-US submission and represents a significant milestone in LENZ’s international expansion strategy to establish VIZZ as a global brand. Presbyopia affects an estimated 1.8 billion people globally, and Europe represents one of the largest markets for vision correction products. LENZ intends to pursue commercialization in Europe through strategic partnerships, complementing partnerships already in place for Greater China, the Republic of Korea and Southeast Asia, Canada, and the Middle East region, and expects to provide further updates as the regulatory review progresses.
“The submission of our Marketing Authorization Application to the EMA is a pivotal milestone for LENZ as we advance our mission to bring VIZZ to patients around the world,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “Europe represents a substantial opportunity, with millions of people affected by presbyopia who currently lack a convenient pharmacological treatment option. We believe the strong clinical data from our CLARITY program, combined with the favorable safety and tolerability profile of VIZZ, positions us well for a successful regulatory review. We look forward to working with the EMA throughout the review process and continue to advance our partnership discussions necessary to bring VIZZ to Europeans living with presbyopia.”
About Presbyopia
Presbyopia is the inevitable loss of near vision associated with aging, impacting the daily lives of nearly all people over the age of 45. As people age, the crystalline lens in their eyes gradually hardens and becomes less able to change shape. This loss of elasticity of the lens reduces the ability of the lens to focus incoming light from near objects onto the retina. Adults over 50 years of age lose, on average, 1.5 lines of near vision every six years. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their mid-40s, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an ECP, with prescription reading or bifocal glasses or multifocal contact lenses.
About VIZZ (aceclidine ophthalmic solution)
VIZZ (aceclidine ophthalmic solution)
VIZZ Indication and Important Safety Information
INDICATION
VIZZ (aceclidine ophthalmic solution)
IMPORTANT SAFETY INFORMATION
- Do not use VIZZ if allergic to any of the ingredients.
- To help avoid potential eye injury or contamination of the product, do not allow the vial tip to touch the eye or any surfaces. Discard the opened vial immediately after use.
- Contact lenses should be removed before using VIZZ. After dosing, contact lenses can be reinserted after 10 minutes.
- If using more than one topical eye medication, the medicines should be administered at least 5 minutes apart.
- Temporary dim or dark vision may be experienced after using VIZZ. Do not drive or operate machinery if vision is not clear.
- Seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced.
ADVERSE REACTIONS
The most common reported adverse reactions of participants were instillation site irritation (
For additional information, please see the full Prescribing Information available at www.VIZZ.com/full-prescribing-information.pdf.
About LENZ Therapeutics
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution)
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. You can identify forward-looking statements by words such as “may,” “will,” “could,” “can,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “poised,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, but not all forward-looking statements will contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the timing and outcome of the European Medicines Agency’s review of the Marketing Authorization Application for VIZZ, the potential commercial availability of VIZZ in Europe, LENZ’s mission to bring VIZZ to patients around the world, and plans for commercialization through strategic partnerships. These statements are based on numerous assumptions concerning LENZ, VIZZ, target markets and regulatory agencies and involve substantial risks, uncertainties and other factors that could cause actual results to differ materially from those projected, expressed or implied by these forward-looking statements, including risks related to regulatory approvals, market conditions, and those risk factors described in the section titled “Risk Factors” in our Quarterly Report on Form 10-Q filed for the quarter ended September 30, 2025 and our subsequent filings with the Securities and Exchange Commission. We cannot assure you that the forward-looking statements in this press release or the assumptions upon which they are based will prove to be accurate. The forward-looking statements in this press release are made as of the date of this press release. Except as otherwise required by applicable law, LENZ disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Contact:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
